<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076943</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-092</org_study_id>
    <nct_id>NCT04076943</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia</brief_title>
  <official_title>A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and&#xD;
      effective for the treatment of anemia in people receiving chemotherapy treatment for cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of three periods:&#xD;
&#xD;
        1. Screening Period up to 28 days&#xD;
&#xD;
        2. Treatment Period of 16 weeks&#xD;
&#xD;
        3. A Follow-up period of 4 weeks.&#xD;
&#xD;
      A total of up to approximately 100 patients will be enrolled to receive roxadustat in an&#xD;
      open-label manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Actual">April 23, 2021</completion_date>
  <primary_completion_date type="Actual">March 26, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change in Hemoglobin within 16 weeks</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The primary efficacy endpoint is maximum change in hemoglobin within 16 weeks from baseline without RBC transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in hemoglobin level</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Mean change in hemoglobin level from baseline to week 16 (without RBC transfusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Change in hemoglobin from baseline at Week 8, 12, 16 (without RBC transfusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBC transfusion</measure>
    <time_frame>Week 5 to Week 16</time_frame>
    <description>Number (%) of patients who had a RBC transfusion from beginning of Week 5 (Day 29)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Chemotherapy Induced Anemia</condition>
  <arm_group>
    <arm_group_label>Roxadustat (FG-4592)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat (FG-4592)</intervention_name>
    <description>Roxadustat will be dosed orally three times a week.</description>
    <arm_group_label>Roxadustat (FG-4592)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of non-myeloid malignancy&#xD;
&#xD;
          2. Anemia caused by cancer treatment (myelosuppressive chemotherapy) defined as Hb ≤10.0&#xD;
             g/dL at screening&#xD;
&#xD;
          3. Planned concurrent treatment of cancer with chemotherapy for at least 8 additional&#xD;
             weeks&#xD;
&#xD;
          4. Estimated life expectancy ≥ 6 months at enrollment (Day 1)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with cancer receiving chemotherapy when the anticipated outcome is cure&#xD;
&#xD;
          2. Patients who are only receiving hormonal products, biological products, cancer&#xD;
             immunotherapy or radiation therapy&#xD;
&#xD;
          3. History of leukemia&#xD;
&#xD;
          4. Patients who have received an RBC transfusion or erythropoietic therapy within 4 weeks&#xD;
             of enrollment&#xD;
&#xD;
          5. Any investigational drug within 8-weeks prior to treatment with roxadustat&#xD;
&#xD;
          6. Anemia due to other etiologies&#xD;
&#xD;
          7. Cardiovascular risks, such as myocardial infarction, stroke, heart failure or&#xD;
             thromboembolic event (e.g., deep vein thrombosis (DVT) or pulmonary embolism) within&#xD;
             previous 6 months of screening&#xD;
&#xD;
          8. Clinically significant or uncontrolled ongoing autoimmune disease (e.g., rheumatoid&#xD;
             arthritis, Crohn's disease, celiac disease, etc.)&#xD;
&#xD;
          9. Known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chemotherapy induced anemia</keyword>
  <keyword>Myelosuppressive chemotherapy</keyword>
  <keyword>Non-Myeloid malignances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

